Evaluating Lipidomic Circuit Modulation in Glaucoma Management

Glaucoma, a sight-threatening condition, is primarily characterized by elevated intraocular pressure (IOP). Despite its importance, the relationship between IOP and glaucoma progression is complex. Livne-Bar et al. (2017) unveiled the neuroprotective potential of lipoxins A4 and B4 (LXA4 and LXB4) in experimental glaucoma. To explore this in a clinical context, I evaluated lipidomic profiles in glaucoma patients and made unexpected findings. Out of a panel of lipid mediators and metabolites Arachidonic acid (AA) and LXA4 levels were selectively elevated, contrary to expectations based on LXA4's neuroprotective role. Investigating the influence of glaucoma medications on human trabecular meshwork cells, I found that latanoprost, a common prostaglandin analogue used as a glaucoma treatment to lower IOP, upregulated key lipidomic elements to produce significantly more LXA4. This result was intriguing because both prostaglandins and LXA4 are lipid mediators derived from the same arachidonic acid substrate. Studying untreated glaucoma patients is challenging, as they often initiate medication early. To approximate this circumstance, I developed a novel rodent model of gradual ocular hypertension (gOHT). Unlike previous models, gOHT exhibited minimal inflammation, significant retinal ganglion cell loss, and vision decline. Cytokine profiling distinguished it from other models that have an IOP spike at induction. Interestingly, the lipidomic profile of this model did not reflect the clinical findings of elevated lipoxins; AA levels were not significantly different compared to controls and lipoxin levels were below detection threshold. This confirmed our earlier finding that upregulation of the AA-lipoxin pathway is instead linked to prostaglandin analogue treatment. Further exploration found that LXA4 does not significantly alter IOP. However, targeting the production of endogenous prostaglandins with the COX inhibitor bromfenac reduced latanoprost's IOP-lowering effects. Thus, a dual mechanism has been uncovered for latanoprost actions that induces parallel pathways to 1) reduce IOP via COX-prostaglandin actions, and 2) inhibit proinflammatory signaling and regulate tissue fibrosis. These findings challenge the current understanding of glaucoma treatment, offering avenues for further research and potential therapeutic advancements.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.